CXCR4 expression in prostate cancer progenitor cells

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Dubrovska, Anna ^a,g   Elliott, Jimmy ^b   Salamone, Richard J ^b   Telegeev, Gennady D ^d   Stakhovsky, Alexander E ^c   Schepotin, Ihor B ^c   Yan, Feng ^b   Wang, Yan ^b   Bouchez, Laure C ^a,f   Kularatne, Sumith A ^a   Watson, James ^b   Trussell, Christopher ^b   Reddy, Venkateshwar A ^a,b,e   Cho, Charles Y ^b   Schultz, Peter G ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c NATIONAL CANCER INSTITUTE   (Ukraine)

^d INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^e Sanofi US   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DOCETAXEL; HERMES ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PLERIXAFOR; TRANSCRIPTION FACTOR FKHRL1; ANTINEOPLASTIC AGENT; CXCR4 PROTEIN, HUMAN; HETEROCYCLIC COMPOUND; STROMAL CELL DERIVED FACTOR 1; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CARCINOGENICITY; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL POPULATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEEDBACK SYSTEM; METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION; CELL PROLIFERATION; CHEMOKINE CXCL12; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MICE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RECEPTORS, CXCR4; TAXOIDS;

EID: 84863180510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031226     Document Type: Article

References (44)

1. Debes JD, Tindall DJ, (2004) Mechanism of Androgen-Refractory Prostate Cancer. N Engl J Med 351: 1488-1490.
2. Arnold JT, Isaacs JT, (2002) Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocrine-Related Cancer 9: 61-73.
3. Vishnu P, Tan WW, (2010) Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 3: 39-51.
4. Dalerba P, Cho RW, Clarke MF, (2007) Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284.
5. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, et al. (2009) The role of PTEN/AKT/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106: 268-273.
6. Maitland NJ, Collins AT, (2008) Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26: 2862-2870.
7. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-1708.
8. Neal DE, Maitland NJ, Collins AT, (2005) CD133, a novel marker for human prostatic epithelial stem cells. Journal of Cell Science 117: 3539-3545.
9. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68: 9703-9711.
10. Miki J, Furusato B, Li H, Gu Y, Takahashi H, et al. (2007) Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-3161.
11. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, et al. (2007) Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinol 46: 1-14.
12. Dubrovska A, Elliott J, Salamone RJ, Kim S, Aimone LJ, et al. (2010) Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin Cancer Res 16: 5692-5702.
13. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, et al. (2004) Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 18: 1240-1242.
14. Engl T, Relja B, Marian D, Blumenberg C, Müller I, et al. (2006) CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 8: 290-301.
15. Singh S, Singh UP, Grizzle WE, Lillard JW Jr, (2004) CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 84: 1666-1676.
16. Burger JA, Burger M, Kipps TJ, (1999) Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94: 3658-3667.
17. Barretina J, Juncà J, Llano A, Gutiérrez A, Flores A, et al. (2003) CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann Hematol 82: 500-505.
18. Vandercappellen J, Van Damme J, Struyf S, (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 28: 226-244.
19. Zlotnik A, (2008) New insights on the role of CXCR4 in cancer metastasis. J Pathol 215: 211-213.
20. Furusato B, Mohamed A, Uhlén M, Rhim JS, (2010) CXCR4 and cancer. Pathol Int 60: 497-505.
21. Ehtesham M, Mapara KY, Stevenson CB, Thompson RC, (2009) CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett 274: 305-312.
22. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, et al. (2006) Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 5: 56.
23. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, et al. (2010) Basal epithelial cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA 107: 2610-2615.
24. Mulholland DJ, Xin L, Morin A, Lawson D, Witte ON, (2009) Lin-Sca-1+ CD49f high stem/progenitors are tumor initiating cells in the PTEN-null prostate cancer model. Cancer Res 69: 8555-8562.
25. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON, (2010) Identification of a cell of origin for human prostate cancer. Science 329: 568-571.
26. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, et al. (2006) CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 66: 32-48.
27. Huang H, Tindall DJ, (2006) FOXO factors: a matter of life and death. Future Oncol 2: 83-89.
28. Miyamoto K, Araki KY, Naka K, Arai F, Takubo K, et al. (2007) Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1: 101-112.
29. Zhu S, Evans S, Yan B, Povsic TJ, Tapson V, et al. (2008) Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells. Circulation 118: 2156-2165.
30. Wu Y, Peng H, Cui M, Whitney NP, Huang Y, et al. (2009) CXCL12 increases human neural progenitor cell proliferation through Akt-1/FOXO3a signaling pathway. J Neurochem 109: 1157-1167.
31. Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, et al. (1998) Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett 426: 271-278.
32. Gomis RR, Alarcón C, He W, Wang Q, Seoane J, et al. (2006) A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci U S A 103: 12747-12752.
33. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
34. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, et al. (2007) Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 67: 61-73.
35. Goel HL, Li J, Kogan S, Languino LR, (2008) Integrins in prostate cancer progression. Endocr Relat Cancer 3: 657-664.
36. Struckhoff AP, Vitko JR, Rana MK, Davis CT, Foderingham KE, et al. (2010) Dynamic regulation of ROCK in tumor cells controls CXCR4-driven adhesion events. J Cell Sci 123: 401-412.
37. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, et al. (2006) Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 5: 3113-3121.
38. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, et al. (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62: 1832-1837.
39. Cooper CR, Chay CH, Pienta KJ, (2002) The Role of αvβ3 in Prostate Cancer Progression. Neoplasia 4: 191-194.
40. Zheng D-Q, Woodward AS, Fornaro M, Tallini G, Languino LR, (1999) Prostatic carcinoma cell migration via αVβ3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59: 1655-1664.
41. Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, et al. (2009) Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 69: 1460-1469.
42. Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, et al. (2009) Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 4: e8377.
43. Passegué E, Wagner EF, Weissman IL, (2004) JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119: 431-443.
44. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, et al. (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667.